Ropsacitinib (PF-06826647) has moved into Phase 2 testing for plaque psoriasis and hidradenitis suppurativa, extending the competitive field of TYK2 kinase inhibition. The program positions the drug as mechanistically distinct from allosteric TYK2 inhibitors such as deucravacitinib (Sotyktu), with PF-06826647 binding the catalytically active TYK2 (JH1) domain. The crossover matters for development strategy because JH1-directed inhibitors could bring different safety, efficacy, and biomarker behavior than JH2 allosteric agents as programs mature in inflammatory dermatology. PF-06826647’s entry also keeps pressure on established IL-17 and JAK/TYK franchises while broadening the clinical data set around TYK2 engagement modes. With both psoriasis and hidradenitis suppurativa in the initial Phase 2 plan, the sponsor is effectively testing the durability of the inhibition approach across two inflammatory diseases that have distinct immunopathology and clinical endpoints.